Pregenen

Exciting news (see attached Press Release), as Pregenen has been acquired by bluebird bio, Inc.(Nasdaq: BLUE), a public gene therapy company based in the Boston area. http://investor.bluebirdbio.com/phoenix.zhtml?c=251820 & p=irol-newsArticle & ID=1943834 & highlight= Pregenen designs and engineers molecules critical to a new generation of cell-based therapies for unmet medical needs. We work with our partners to apply our tools, services and reagents to increase the reliability, efficacy and safety of a new wave of therapies harnessing the specificity and functional power of molecules and cells produced by the body. Our approach is based on proprietary methods, reagents and software tools we have developed or licensed from leading laboratories in the genome engineering field. The customized endonucleases developed on our engineering platform are optimized for high target specificity and low cellular toxicity, and the lead therapeutic candidates we have generated are directed to cancer and infectious disease targets.